| | | |   | | | | By Ed Silverman Molly Ferguson for STAT The FDA greatly outpaced its European counterpart in reviewing and approving new cancer treatments over a recent 10-year period. Read More | | By Jonathan Wosen and Akila Muthukumar Adobe The once-daily pill, known as Olumiant, was approved after clinical trials showed that treated patients regrew much of their lost hair. Read More | | By Nicholas St. Fleur Keisha Okafor for STAT In this "Color Code" episode, we explore the barriers to achieving more diverse clinical trials and what needs to be done to topple them. Read More | | Sponsor content by ICON CLINICAL RESEARCH Early engagement and regulatory considerations for drug development by emerging biotechs Despite robust funding and government initiatives for the development of orphan drugs and personalized medicines, small emerging biotech companies are typically very lean on resources, lacking the infrastructure required to bring their innovation to the market. Download this whitepaper, and find out how to navigate the complexities of drug development as a small biotech organization. Gain insights into key considerations for forming successful partnerships, and learn more about why it's crucial to engage a regulatory strategist in all aspects of drug development. | | By Jason Mast Adobe The results of Day One's brain cancer drug are an early but rare glimmer of progress in a disease that has seen little in the last 30 years. Read More | |
No comments